The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2021 | Maintenance therapy after allogeneic HSCT in MDS
Francesco Onida, MD, University of Milan, Milan, Italy, gives a summary of his talk on maintenance therapy after allogeneic hematopoietic stem cell transplantation (HSCT) for patients with myelodysplastic syndromes (MDS). Dr Onida highlights the need for more data and prospective clinical trials of maintenance therapy for patients with MDS. Dr Onida also outlines the use of low-dose azacitidine and panobinostat in patients with MDS. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
